Capecitabine
- PDF / 169,812 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 82 Downloads / 155 Views
1
S
Various toxicities: 3 case reports In a retrospective study of 89 patients with metastatic breast cancer who were treated with capecitabine between December 2001 and May 2008, three elderly women [exact ages not stated] were described who developed nausea and vomiting (1 patient), palmar and plantar erythema (1 patient) and diarrhoea (1 patient) during treatment with capecitabine [not all dosage stated, times to reactions onsets and outcomes not stated]. The women, who had locally advanced or metastatic breast cancer, were scheduled to receive oral capecitabine. Of whom, one woman had been receiving full-dose oral capecitabine 1000 mg/m2 twice daily on day 1–14 every three weeks and developed grade III nausea and vomiting. The remaining two women developed grade IV palmar and plantar erythema and grade IV diarrhoea, respectively. Hence, capecitabine was stopped for women who had diarrhoea and palmar and plantar erythema. The woman with diarrhoea, was hospitalised, and during hospitalisation, she died due to chest infection. Author comment: "One (1%) patient in the full dose group experienced grade 3 nausea and vomiting". "Twelve (13%) patients stopped treatment due to toxicity, one (1%) due to grade 4 [palmar and plantar erythema] . . . one (1%) due to grade 4 diarrhoea". Kotsori AA, et al. Moderate dose capecitabine in older patients with metastatic breast cancer: A standard option for first line treatment?. Breast 19: 377-381, No. 5, Oct 2010. Available from: URL: http://doi.org/10.1016/j.breast.2010.03.023 803438131 United Kingdom
0114-9954/19/1782-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 7 Dec 2019 No. 1782
Data Loading...
